Natera, Inc. (NTRA) Stock
NTRA Key Statistics
About Natera, Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
CEO: Steven Leonard Chapman. Company website
NTRA — Frequently Asked Questions
What is the NTRA stock price today?
Natera, Inc. (NTRA) trades at $369.39, up 0.84% on the day, as of Sep 20, 2026 15:01 UTC.
What is Natera, Inc.'s market cap?
Natera, Inc. has a market capitalisation of $52.90B, calculated from the live NTRA share price and shares outstanding.
What is the P/E ratio of NTRA?
NTRA has no meaningful price-to-earnings ratio: Natera, Inc. lost $1.36 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Natera, Inc. make?
Natera, Inc. generated revenue of $2.71B over the trailing twelve months, which puts the stock at 19.54 times sales.
What is the 52-week range for NTRA?
NTRA has traded between $157.43 and $369.69 over the past 52 weeks, and the last price is 0.1% below that high.
Is Natera, Inc. profitable?
No. Natera, Inc. is loss-making, with a net margin of -7.11% over the trailing twelve months.
What is the analyst price target for NTRA?
Wall Street analysts rate NTRA Buy, with an average price target of $335.07, 9.3% below the current price.
What sector is Natera, Inc. in?
Natera, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Natera, Inc.?
Steven Leonard Chapman is the chief executive of Natera, Inc., which employs 6,138 people.
Where can I track NTRA in real time?
QFI Terminal shows NTRA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NTRA live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NTRA in Terminal See plans